SAB4200795
Anti-Exendin-4 antibody produced in rabbit
affinity isolated antibody
Synonyme(s) :
Anti-Exenatide
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
rabbit
Niveau de qualité
Forme d'anticorps
affinity isolated antibody
Type de produit anticorps
primary antibodies
Clone
polyclonal
Forme
buffered aqueous solution
Concentration
~1 mg/mL
Technique(s)
indirect ELISA: 0.125-0.25 μg/mL using 1 μg/mL Exendin-4 protein for coating
Numéro d'accès UniProt
Conditions d'expédition
dry ice
Température de stockage
−20°C
Modification post-traductionnelle de la cible
unmodified
Description générale
Exendin-4 is an incretin mimetic 39-amino-acid peptide found in venom from the Gila monster (Helicoderma suspectum). Exendin-4 belongs to the glucagon-secretin family of peptide hormones and neuropeptides. It acts as a potent agonist of the GLP-1 receptor and is an insulinotropic agent (promotes insulin secretion) with a long half-life.
Exendin-4 mimics the activity of mammalian incretin hormone glucagon-like peptide 1 (GLP-1) and thus play a role in the control of glucose. This includes the secretion of insulin in a glucose-dependent manner, negative regulation of high glucagon secretion, and increased duration of stomach emptying. In type 2 diabetes patients, this peptide can be administered subcutaneously for glycemic control, when metformin is unable to produce adequate results. Exendin-4 promotes the neogeneration and proliferation of β-cells, and thus aids in the regeneration of pancreas. It acts as a ligand to exendin receptor and leads to an elevation of acinar cell cAMP levels.
Anti-Exendin-4 antibody specifically recognizes synthetic Exendin-4 and does not cross react with GLP-1.
Exendin-4 mimics the activity of mammalian incretin hormone glucagon-like peptide 1 (GLP-1) and thus play a role in the control of glucose. This includes the secretion of insulin in a glucose-dependent manner, negative regulation of high glucagon secretion, and increased duration of stomach emptying. In type 2 diabetes patients, this peptide can be administered subcutaneously for glycemic control, when metformin is unable to produce adequate results. Exendin-4 promotes the neogeneration and proliferation of β-cells, and thus aids in the regeneration of pancreas. It acts as a ligand to exendin receptor and leads to an elevation of acinar cell cAMP levels.
Anti-Exendin-4 antibody specifically recognizes synthetic Exendin-4 and does not cross react with GLP-1.
Immunogène
synthetic peptide corresponding to the C-terminal sequence of Heloderma suspectum (Gila monster) Exendin-4 , conjugated to KLH
Application
The antibody may be used in various immunochemical techniques including ELISA
Forme physique
Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Autres remarques
This product is for R&D use only, not for drug, household, or other uses.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Faites votre choix parmi les versions les plus récentes :
Certificats d'analyse (COA)
Lot/Batch Number
Vous ne trouvez pas la bonne version ?
Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Yahiya Y Syed et al.
Drugs, 75(10), 1141-1152 (2015-06-14)
Exenatide extended-release (exenatide ER) [Bydureon(®)] is a glucagon-like peptide-1 receptor agonist, approved for the treatment of type 2 diabetes mellitus. It is injected subcutaneously by patients once weekly, with no dose titration required. This article updates an earlier review of
Ralph A DeFronzo et al.
Diabetes care, 28(5), 1092-1100 (2005-04-28)
This study evaluates the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses. A triple-blind, placebo-controlled, 30-week study at 82 U.S. sites
J Eng et al.
The Journal of biological chemistry, 267(11), 7402-7405 (1992-04-15)
The recent identification in Heloderma horridum venom of exendin-3, a new member of the glucagon superfamily that acts as a pancreatic secretagogue, prompted a search for a similar peptide in Heloderma suspectum venom. An amino acid sequencing assay for peptides
Masayuki Arakawa et al.
Diabetes, 59(4), 1030-1037 (2010-01-14)
Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4 has direct beneficial effects on the cardiovascular system. However, their effects on atherosclerogenesis have not been elucidated. The aim of this study was to investigate the
G Xu et al.
Diabetes, 48(12), 2270-2276 (1999-12-02)
Diabetes is a disease of increasing prevalence in the general population and of unknown cause. Diabetes is manifested as hyperglycemia due to a relative deficiency of the production of insulin by the pancreatic beta-cells. One determinant in the development of
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique